Barbara Buttin, M.D.
- Gynecologic Cancers
- Minimally Invasive Surgery
- Robotic Surgery
- Associate Clinical Professor, Department of Surgery
- Referring Physicians Phone(847) 746-9990
- Referring Physicians Fax(847) 342-4089
- Referring Physicians Email[email protected]
Barbara Buttin, M.D., joined City of Hope® Cancer Center in September 2021, where she evaluates and treats patients with gynecologic malignancies, including ovarian, cervical, uterine, vaginal and vulvar cancers.
Dr. Buttin received her medical degree from Drexel University College of Medicine, formerly Hahnemann University, in Philadelphia. She completed a residency in obstetrics and gynecology and a fellowship in gynecologic oncology at Washington University School of Medicine in St. Louis, Missouri.
Patient-focused care is an integral part of improving health outcomes, which is why Dr. Buttin centers her treatment on the individualized needs of the whole patient. Dr. Buttin also incorporates evidence-informed supportive therapies to help combat cancer-related side effects. She has a special interest in minimally invasive surgical techniques, including robotic surgery, having performed over 1,500 cases to date, and the newer application of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. Dr. Buttin is also focused on growing the clinical trials portfolio at City of Hope to provide patients with more treatment options.
Working in a variety of health care settings, Dr. Buttin has over 15 years of experience as a gynecologic oncologist. She is an active member of several professional organizations including the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology.
Location
Chicago Cancer Center
Zion, IL 60099
Education & Experience
Board Certifications
- Gynecologic Oncology, Obstetrics and Gynecology — American Board of Obstetrics and Gynecology
Degrees
- Hahnemann University School of Medicine, Philadelphia, PA
Residency
- Obstetrics and Gynecology — Washington University School of Medicine, St. Louis, MO
Fellowship
- Gynecologic Oncology — Washington University School of Medicine, St. Louis, MO
Awards & Memberships
Awards
- 2017, Chicago Magazine’s List of Top Cancer Doctors for Gynecologic Oncology
- 2014, Appointed Member of the Society of Gynecologic Oncology Policy, Quality and Outcomes Task Force
- 2013, Founder of the CDH Robotic Surgery Working Group and Appointed Member of the CDH Robotic Surgery Steering Committee
- 2010–2011, Appointed member of the Gynecologic Oncology Group Committee on Experimental Medicine
- 2009–2011, Northwestern Memorial Foundation Young Investigator Award
- 2008–2010, Sidney Kimmel Foundation for Cancer Research Kimmel Translational Science Award
- 2008–2011, Appointed Member of the Society of Gynecologic Oncologists Education Committee
- 2007–2011, Recipient of Annual Outstanding Teacher Award from students of the Northwestern Feinberg School of Medicine
- 2007–2008, Appointed Member of the Society of Gynecologic Oncologists Clinical Practice Committee
- 2006, Appointed Member of the Society of Gynecologic Oncologists Education Resource Panel (Speakers Bureau) on Hereditary Cancers
Memberships
- Fellow, American College of Obstetricians and Gynecologists
- Full Member, Society of Gynecologic Oncology
Publications
- Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic Oncology Reports. 31:100532, 2020 Feb.
- Winder AD, Maniar K, Wei J, Liu D, Scholtens DM, Lurain JR, Schink J, Buttin B, et al. Synuclein-γ (SNCG) in Uterine Serous Carcinoma Impacts Survival: An NRG Oncology/ Gynecologic Oncology Group study. Cancer 2017;123(7):1144-1155
- Strohl A, Mori K, Akers S, Bshara W, Buttin B, Frederick PJ, Helenowski IB, Morrison CD, Odunsi K, Schink JC, Scholtens DM, Wei JJ, Kim JJ. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. J Ovarian Res 2016;9(1):75.
- McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, Wei JJ. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. Mod Pathol 2012;25(12):1644-53.
- Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ, Buttin BM. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol 2009;114(2):293-8.
- Hoekstra AV, Jairam-Thodla A, Rademaker A, Singh DK, Buttin BM, Lurain JR, Schink JC, Lowe MP. The impact of robotics on practice management of endometrial cancer: transitioning from traditional surgery. Int J Med Robot 2009;5(4):392-7.
- Hoekstra AV, Morgan JM, Lurain JR, Buttin BM, Singh DK, Schink JC, Lowe MP. Robotic surgery in gynecologic oncology: Impact on fellowship training. Gynecol Oncol 2009; 114(2):168-72.
- Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink JC. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009;113(1):63-7.
- Hoekstra AV, Ward EC, Hardt JL, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 2008;108(3):609-18.
- Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ. The regulation and function of the forkhead transcription factor, FOXO1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 2008; 149(4):1942-50.